Skip to main content
    S

    Sarepta Therapeutics Inc (SRPT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $15.13
    -0.94 (-5.85%)

    Market Cap: $1.72B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Sarepta Therapeutics Inc (SRPT) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Sarepta Therapeutics (SRPT) trades at 0.8x sales and 1.0x book value. Its P/S of 0.8x is below its 5-year median of 7.7x. Its forward P/E is 16.2x.

    Current Multiples

    Its free cash flow yield is 11.0%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E16.2x
    Price to sales0.8x
    Price to book1.0x
    Price to FCF9.1x
    EV/FCF11.3x
    PEGN/A
    FCF yield11.0%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 92.7% below 11.0x and its P/B is 88.9% below 9.0x.

    MultipleCurrent5-year median10-year median
    P/S0.8x7.7x11.0x
    P/B1.0x8.8x9.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 119 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 1.0x in 2025 to 276.4x in 2016. 2025 was the lowest of those years.

    Year endPriceP/EP/SP/B
    2025$21.52N/A1.0x2.0x
    2024$121.5933.0x6.3x8.6x
    2023$96.43N/A7.2x11.8x
    2022$129.58N/A12.2x29.6x
    2021$90.05N/A10.2x7.8x
    2020$170.49N/A24.6x17.6x
    2019$129.04N/A24.9x11.7x
    2018$109.13N/A24.1x7.3x
    2017$55.64N/A21.6x4.5x
    2016$27.43N/A276.4x4.4x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    Frequently Asked Questions About SRPT

    What is SRPT's forward P/E ratio?

    Sarepta Therapeutics has a forward P/E ratio of 16.2x.

    What is SRPT's price to sales ratio?

    Sarepta Therapeutics has a price to sales ratio of 0.8x.